Clinical Endpoint Bioequivalence study [Regulatives / Guidelines]

posted by sury – India, 2019-04-09 06:19 (1026 d 09:32 ago) – Posting: # 20133
Views: 2,263

» You're referring to the draft guidance on miconazole buccal tablets, right ? Would be easier for us if you could say so straight away and link the guidance...

yes, i am actually referring to the miconazole buccal tablets drug

» For the statistical analysis the draft guidance refers to another draft guidance, on adapalene + benzoyl peroxyde. Did you read it ? Did you see anywhere a mention of log-transformation ? And why are you changing acceptance limits of -0.20 to +0.20 into 80.00 - 120.00 ?

There is no where in the draft guidance on what data (Untransformed and Log Transformed) to conduct the statistical Analysis.


Edit: Full quote removed. Please delete everything from the text of the original poster which is not necessary in understanding your answer; see also this post! [Ohlbe]

Complete thread:

Activity
 Admin contact
21,858 posts in 4,574 threads, 1,554 registered users;
online 21 (0 registered, 21 guests [including 19 identified bots]).
Forum time: Saturday 14:52 CET (Europe/Vienna)

Truth in science can be defined as the working hypothesis best suited
to open the way to the next better one.    Konrad Lorenz

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5